Last edition
News about "Sanofi"
CORXEL Signs Agreement with Sanofi for Aficamten in Greater China Markets
Aficamten is an investigational, next-in-class selective small molecule cardiac myosin inhibitor discovered and developed globally by Cytokinetics.
Sanofi | 02/01/2025 | By Aishwarya
Sanofi Begins Shipping BEYFORTUS in US
Sanofi has started shipping BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection doses in the US to private healthcare providers and to the Centers for Disease Control and Prevention for its vaccines for children program.
Sanofi | 18/09/2024 | By Aishwarya
Sanofi Reveals Positive Results of Tolebrutinib in HERCULES Phase 3 Study
In the HERCULES study, nrSPMS was defined at baseline as having an SPMS diagnosis with an expanded disability status scale (EDSS) score between 3.0 and 6.5, no clinical relapses for the previous 24 months and documented evidence of disability accumulation in the previous 12 months.
Sanofi | 03/09/2024 | By Aishwarya | 100
Sanofi Starts Shipping US Influenza Vaccines for 2024-25
Sanofi has begun shipped its first influenza (flu) vaccines across the U.S. in preparation for the 2024–25 flu season.
Sanofi | 11/07/2024 | By Aishwarya | 339
Sanofi and Biovac to Manufacture Inactivated Polio Vaccines in Africa
Sanofi has signed local manufacturing partnership with Biovacto to produce inactivated polio vaccines (IPV) in Africa.
Sanofi | 27/06/2024 | By Aishwarya | 239
Sanofi Announces Complete Acquisition of Inhibrx
Sanofi has recently announced the complete acquisition of Inhibrx, Inc.
Sanofi | 31/05/2024 | By Aishwarya
Sanofi, Formation Bio and OpenAI to Develop AI-Powered Software
Sanofi, Formation Bio and OpenAI have announced their collaboration to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently.
Sanofi | 21/05/2024 | By Aishwarya | 147
Sartorius, Sanofi to Develop End-to-End Platform for Downstream Process Intensification
Sartorius has joined hands with Sanofi to develop an end-to-end platform for integrated and continuous downstream bioprocessing.
Sanofi | 14/05/2024 | By Aishwarya | 345
Fulcrum Signs License Deal with Sanofi for Development of Losmapimod in FSHD
Fulcrum Therapeutics has entered into a collaboration and license agreement with Sanofi for the development and commercialization of losmapimod.
Sanofi | 14/05/2024 | By Aishwarya
Sanofi Invests EUR 1 Billion in France to Expand its Biomanufacturing Sites
Sanofi has made an investment of more than EUR 1 billion to create new bioproduction capacity at its sites in Vitry-sur-Seine (Val de Marne), Le Trait (Seine-Maritime) and Lyon Gerland (Rhône).
Sanofi | 13/05/2024 | By Aishwarya | 170
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy